The upcoming two-day review in June for two of bluebird bio’s gene therapies will end a surprising fallow period for reviews by the US Food & Drug Administration’s external Cellular, Tissue & Gene Therapies Advisory Committee (CTGTAC).
Gene Therapy Reviews Return To US FDA Advisory Committee Schedule
The upcoming review of two novel gene therapies from bluebird bio marks will be the first time the US FDA’s CTGTAC has met for a genetic product review in five years. That is a surprisingly long gap – and one that probably will not be repeated.
